Syngene International Adopts Genedata Screener as Collaborative Solution for In Vitro Assay Analysis

Genedata Screener used to ensure standardized assay data and data flow across partners

BASEL, Switzerland, Nov. 28, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announces that Syngene International has become the first Indian contract research, development, and manufacturing organization (CRDMO) to leverage Genedata Screener®, the industry gold standard for assay analytics, as their primary analysis tool for in vitro screening assays.

"We use Genedata Screener for in vitro biochemical and cell-based screening assay data analysis, and it's become the analysis tool we rely on for this data," said Jayashree Aiyar, Chief Scientific Officer, Syngene International. "The platform is easy to use so it took minimal effort for our scientists to become proficient. With Genedata in place, it's easier to work with our partners and our analysis much faster and more robust."

"We could begin using it quickly, thanks to support from the Genedata Team. After a brief, guided initial setup we could instantly centralize and easily manage our data," said Anuradha Ramanathan, Director, Discovery Biology, Syngene International. "With multiple technologies, partners, software, and users, managing our data pipeline is critical to deliver for our partners. Genedata centralizes all of that into one place and makes it much easier to manage."

Genedata Screener streamlines data management and analysis for all screening and assay development operations into one platform. It validates raw data and assay result quality and consolidates information across the enterprise and external collaborators.

"We are pleased that Syngene has adopted Genedata Screener to facilitate easier data exchange with their partners," said Othmar Pfannes, Ph.D., President of Genedata. "We see a way to dramatically accelerate biopharma R&D by supporting CRDMOs and their partners in the biopharma industry in harmonizing data analytical workflows and streamlining the collaboration between them."

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | X | YouTube

About Syngene International

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit http://www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG)report, visit https://esgreport.syngeneintl.com

Contact

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Media Contact

Allison Kurz, Genedata, +41 61 511 84 00, pr@genedata.com, www.genedata.com

View original content to download multimedia:https://www.prweb.com/releases/syngene-international-adopts-genedata-screener-as-collaborative-solution-for-in-vitro-assay-analysis-302316358.html

SOURCE Genedata